Terms: = Brain cancer AND MYD88, Q99836, MYD88D, 4615 AND Prognosis
13 results:
1. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract] [Full Text] [Related]
2. Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain.
Blazquez R; Chuang HN; Wenske B; Trigueros L; Wlochowitz D; Liguori R; Ferrazzi F; Regen T; Proescholdt MA; Rohde V; Riemenschneider MJ; Stadelmann C; Bleckmann A; Beißbarth T; van Rossum D; Hanisch UK; Pukrop T
Oncogene; 2022 Nov; 41(46):5008-5019. PubMed ID: 36224342
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic significance of myd88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
[TBL] [Abstract] [Full Text] [Related]
4. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
[TBL] [Abstract] [Full Text] [Related]
5. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract] [Full Text] [Related]
6. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
[TBL] [Abstract] [Full Text] [Related]
7. myd88 Mutation in Elderly Predicts Poor prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract] [Full Text] [Related]
8. Bioinformatic analysis of gene expression and methylation regulation in glioblastoma.
Wang W; Zhao Z; Wu F; Wang H; Wang J; Lan Q; Zhao J
J Neurooncol; 2018 Feb; 136(3):495-503. PubMed ID: 29168084
[TBL] [Abstract] [Full Text] [Related]
9. Primary Vitreoretinal Lymphoma -- A Review.
Araujo I; Coupland SE
Asia Pac J Ophthalmol (Phila); 2017; 6(3):283-289. PubMed ID: 28558176
[TBL] [Abstract] [Full Text] [Related]
10. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract] [Full Text] [Related]
11. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.
Minnema MC; Kimby E; D'Sa S; Fornecker LM; Poulain S; Snijders TJ; Kastritis E; Kremer S; Fitsiori A; Simon L; Davi F; Lunn M; Castillo JJ; Patterson CJ; Le Garff-Tavernier M; Costopoulos M; Leblond V; Kersten MJ; Dimopoulos MA; Treon SP
Haematologica; 2017 Jan; 102(1):43-51. PubMed ID: 27758817
[TBL] [Abstract] [Full Text] [Related]
12. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract] [Full Text] [Related]
13. Recurrent mutations of CD79B and myd88 are the hallmark of primary central nervous system lymphomas.
Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
[TBL] [Abstract] [Full Text] [Related]
